No significant toxicities observed in 11 patients included in study; 10 were alive at median follow-up of 2.6 years.

- Company Initiating Planning of Phase 2 Trial of Elraglusib in Children, Adolescents, and Adults with Refractory/Resistant Ewing Sarcoma CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) ...

CHICAGO -- High-dose ifosfamide proved more effective at prolonging event-free survival (EFS) and overall survival (OS) than topotecan plus cyclophosphamide in relapsed/refractory Ewing sarcoma, ...

Actuate Therapeutics, Inc. has announced the completion of the Phase 1 study evaluating its drug elraglusib in pediatric patients with refractory malignancies, specifically Ewing Sarcoma (EWS). The ...

Survival rates for children with multi-metastatic Ewing’s sarcoma — a kind of bone cancer which has spread to multiple parts of the body — are ‘dismal’, scientists say. The five-year survival rate for ...

Variations in the approach to lung metastases in osteosarcoma among pediatric and adult patients. ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable ...

HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer ...

Ewing sarcoma is a fast-growing form of bone and soft tissue cancer that strikes about 200 children and young adults per year in the United States. Caught early, before the tumors have spread, the ...

Sorafenib, gamma-secretase inhibitor, and bortezomib as potential therapeutic agents for hepatoblastoma. Background: We report data of long term follow up of 883 patients with localized osteosarcoma ...